RecruitingNot Applicable

Impact of Immune Status on Secondary Infections in Patients With Acute Respiratory Failure

Germany200 participantsStarted 2024-07-10

Plain-language summary

This is a retrospective observational study over the period 1/2019 - 02/2024 with the aim of identifying patients with a predisposition to secondary infections.

Who can participate

Age range7 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male and female acute respiratory distress syndrome patients who had an immune status within 48 h of admission * Patients who received intensive care treatment for acute respiratory distress syndrome ward 8i at Charité in the period from 01/2019 to 02/2024 with a maximum follow-up period of 90 days Exclusion Criteria: * None

What they're measuring

Herpes simplex reactivation

Timeframe: 01/2019- 12/2025

Cytomegalovirus reactivation

Timeframe: 01/2019- 12/2025

Epstein Barr virus reactivation

Timeframe: 01/2019- 12/2025

B cells (CD19 positive)

Timeframe: 01/2019- 12/2025

Natural killer cells Cells (CD16 pos)

Timeframe: 01/2019- 12/2025

T helper cells (CD4)

Timeframe: 01/2019- 12/2025

Cytotoxic T cells (CD8)

Timeframe: 01/2019- 12/2025

HLA-DR expression on monocytes

Timeframe: 01/2019- 12/2025

Trial details

NCT IDNCT06511622

SponsorCharite University, Berlin, Germany

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-03-31

Contact for this trial

Claudia Spies, MD, Prof.

+49 30 450 55 11 02 claudia.spies@charite.de

View on ClinicalTrials.gov More ARDS trials